Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), is associated with statistically fewer heart attacks than Boston Scientific's Taxus® DES. Dr. Martin B. More at...
The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy -- heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding. More at...
Most elective angioplasties are performed without first conducting a noninvasive stress test to determine whether the procedure is necessary, according to a study published Wednesday in the Journal of the American Medical Association, the Milwaukee Journal Sentinel reports. For the study, researchers analyzed 23,887 Medicare claims and 1,630 private insurance claims. More at...
During heart failure the body reacts to the production of the hormone aldosterone. Too much aldosterone can stiffen and damage the muscles of the heart. Dutch researcher Luc Roumen has optimised compounds that inhibit the production of this hormone and looked at their optimum dosage. The compounds were manufactured by the companies Schering-Plough and SyMO-Chem BV and a drug patent has been applied for. Luc Roumen has developed a new therapy for the prevention of heart failure. More at...
Boston Scientific Corporation (NYSE: BSX) announced positive one-year results from the Intercontinental and European launch phases of its global TAXUS OLYMPIA registry, the world's largest prospective, post-approval registry for a single drug-eluting stent (DES). More at...
Boston Scientific Corporation (NYSE: BSX) announced results from an analysis of the HORIZONS AMI trial. More at...
A blunt traumatic injury to the aorta, the body's main artery, is one of the leading causes of death following a vehicle crash. If it is not treated rapidly, the patient is at serious risk for artery rupture, which is nearly always fatal. Surgeons from the University of Maryland Medical Center have evaluated various treatments for this type of traumatic aortic injury, including a newer, less invasive procedure that enables them to fix the artery without making an incision. More at...
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal™ Evolution™ Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. More at...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment